Publications

A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase 2 Trial of Pacibekitug Subcutaneous Quarterly or Monthly in Patients With Elevated hs-CRP and Chronic Kidney Disease: TRANQUILITY 90-Day Results

August 2025

European Society of Cardiology Congress

IL6 genetic perturbation mimicking IL-6 inhibition is associated with lower cardiometabolic risk

August 2025

Nature Cardiovascular Research

Human Genetics Informing Drug Development in Cardiovascular Disease: Interleukin-6 Signaling as a Case Study

August 2025

Circulation: Genomic and Precision Medicine

Prevalence of Thyroid Eye Disease (TED) in the United States

May 2025

Association for Research in Vision and Ophthalmology Annual Conference

The role of IL-6 in thyroid eye disease: An update on emerging treatments

April 2025

Frontiers in Ophthalmology

Real World Management Patterns and Outcomes in Thyroid Eye Disease: A Claims Analysis

March 2025

North American Neuro-Ophthalmology Society

Human Genetic Evidence to Inform Clinical Development of IL-6 Signaling Inhibition for Abdominal Aortic Aneurysm

February 2025

Arteriosclerosis, Thrombosis, and Vascular Biology

IL-6 and Cardiovascular Risk: A Narrative Review

November 2024

Current Atherosclerosis Reports

Effect of IL-6 Inhibition on Lipoprotein(a) Levels: A Systematic Review and Meta-Analysis

October 2024

Cardiometabolic Health Congress

Utilization of High-Sensitivity C-Reactive Protein Testing in Primary and Secondary ASCVD Prevention

October 2024

Cardiometabolic Health Congress

Evaluating TOUR006 in Participants with Chronic Kidney Disease and Elevated Hs-CRP: Rationale and Design of the TRANQUILITY Phase 2 Study

August 2024

American Society of Preventive Cardiology Congress

Modeling to Inform Dose Selection for a Phase 2b Trial Investigating TOUR006, a Fully Human Anti-IL-6 Antibody, for Treatment of Thyroid Eye Disease

May 2024

Association for Research in Vision and Ophthalmology Annual Conference